Merck, Moderna Stocks Soar After Melanoma Trial Success
Shares of Moderna and Merck soared on Wednesday morning after a study showed that a vaccine they produced had promising results when it comes to fighting skin cancer. A late-stage trial showed that the mRNA vaccine helped reduce the recurrence of melanoma. Sam Fazeli of Bloomberg Intelligence has more. (Source: Bloomberg)
This is a summary aggregated from Bloomberg Markets. Read the complete article on the original site:
Read full article at Bloomberg Markets
